2024-11-15T11:01:00-06:00 2023-12-31 454084437 WARREN AVERETT LLC 2500 ACTON ROAD BIRMINGHAM AL 35243 990 2023-01-01 630288868 SOUTHERN RESEARCH INSTITUTE SOUT 2055812000 2000 NINTH AVENUE SOUTH BIRMINGHAM AL 352555305 DAVID A RUTLEDGE SENIOR ADVISOR OF FINANCE 2055812000 2024-11-15 1 1 MEGAN RANDOLPH P00989558 2059794100 2024-11-01 2023 2024-10-15 13:58:12Z DAVID A RUTLEDGE 2000 NINTH AVENUE SOUTH BIRMINGHAM AL 352555305 461400010 0 X WWW.SOUTHERNRESEARCH.ORG X 1941 AL TO OFFER RESEARCH & TECHNOLOGY SERVICES TO SUPPORT INDUSTRY AND FEDERAL GOVERNMENT AGENCIES. TO BE OPERATED FOR THE BENEFIT OF THE UNIVERSITY OF ALABAMA AT BIRMINGHAM. 14 10 290 10 0 0 45128927 7258198 52870532 38681839 51621415 3731361 30734 88562 149651608 49759960 0 0 0 0 28685474 28444077 0 0 0 28433399 27520693 57118873 55964770 92532735 -6204810 211179645 242110174 30745121 63239300 180434524 178870874 X TO OFFER RESEARCH AND TECHNOLOGY SERVICES TO SUPPORT THE LIFE SCIENCES, ENERGY, AND ENVIRONMENTAL PROTECTION INDUSTRIES. THE ORGANIZATION PURSUES ENTREPRENEURIAL AND COLLABORATIVE INITIATIVES TO DEVELOP AND MAINTAIN A PIPELINE OF INTELLECTUAL PROPERTY AND INNOVATIVE TECHNOLOGIES THAT CONTRIBUTE TO THE GROWTH OF THE ORGANIZATION AND POSITIVELY IMPACT REAL-WORLD PROBLEMS. 1 0 22982164 0 17053914 CRO SERVICES PROVIDES DRUG DISCOVERY AND PRE-CLINICAL DRUG DEVELOPMENT TO PHARMACEUTICAL AND BIOTECHNOLOGY ON AN OUTSOURCED BASIS. SOUTHERN RESEARCH INSTITUTE HAS CAPABILITIES IN ALL PHASES OF THE EARLY-STAGE DRUG DISCOVERY AND DEVELOPMENT PROCESS AND PROVIDES CLIENTS WITH COMPREHENSIVE SERVICES AND SUPPORT TO ASSIST THEM IN STREAMLINING THEIR CUSTOM DRUG DISCOVERY AND DEVELOPMENT PROGRAMS. SOME OF SOUTHERN RESEARCH INSTITUTE'S SIGNIFICANT PRE-CLINICAL RESEARCH ACCOMPLISHMENTS INCLUDE: DEMONSTRATED THE EFFICACY OF COMBINATION CHEMOTHERAPY IN MICE, LEADING THE WAY FOR THE DEVELOPMENT OF THERAPEUTIC APPROACHES WITH IMPROVED CLINICAL OUTCOMES IN CERTAIN CANCERS, PERFORMED PRE-CLINICAL DRUG DEVELOPMENT EVALUATIONS AND ANALYSES ON APPROXIMATELY HALF OF THE FDA-APPROVED CANCER THERAPEUTICS CURRENTLY ON THE MARKET, AND CONTRIBUTED TO THE DEVELOPMENT OF THE FIRST DRUG DELIVERY TECHNOLOGY FOR THE EXTENDED RELEASE OF SYNTHETIC AGENTS THAT PROMOTE THE TREATMENT OF PROSTATE CANCER. 17400139 0 17959485 SCIENTIFIC PLATFORMS HAS ACCOMPLISHED INNOVATIVE RESEARCH IN THE AREAS OF CANCER, INFECTIOUS DISEASE, AND NEUROSCIENCE. WITH A FOCUS ON THE DISCOVERY OF NEW, SMALL-MOLECULE THERAPEUTICS AND THE UNDERSTANDING OF HOW THESE MOLECULES WORK, DRUG DISCOVERY CARRIES OUT TRANSLATIONAL SCIENCE DESIGNED TO INVENT SMALL MOLECULES AND ADVANCE THEM FROM THE DESIGN STAGE TO THE CLINIC. GOVERNMENT FUNDING SUPPORTS OUR EFFORTS IN PIONEERING NEW SCIENTIFIC AREAS OF DRUG DISCOVERY. THE SCIENTIFIC PLATFORMS' STAFF PROVIDES EXPERTISE IN MEDICINAL CHEMISTRY, MOLECULAR BIOLOGY, BIOCHEMISTRY, AND HIGH-THROUGHPUT SCREENING TECHNOLOGIES, ALL FOCUSED ON MAKING DISCOVERIES THAT WILL CONTRIBUTE TO IMPROVING HUMAN HEALTH. THE SCIENTIFIC PLATFORMS' TEAM HAS BEEN VERY EFFECTIVE IN ITS EFFORTS AND HAS DISCOVERED MORE THAN 20 DRUGS THAT HAVE ENTERED CLINICAL TRIALS AND SIX DRUGS THAT HAVE BEEN APPROVED BY THE FDA FOR USE IN THE TREATMENT OF CANCER. 1076156 0 1124921 SOUTHERN RESEARCH'S STEM EDUCATION OUTREACH PROGRAM IS INVOLVED IN A WIDE VARIETY OF PROGRAMS THAT IMPACT STUDENTS AND TEACHERS IN ALABAMA. THE MISSION OF SR'S STEM PROGRAM IS TO ENHANCE 6TH - 12TH GRADE STEM EDUCATION BY DRAWING UPON THE EXPERTISE AND SCHOLARLY CONTRIBUTIONS OF THE SOUTHERN RESEARCH COMMUNITY. WE AIM TO DEFINE AND EXEMPLIFY EFFECTIVE STEM EDUCATION TO MAXIMIZE STUDENTS' READINESS TO EXCEL IN A RAPIDLY CHANGING WORLD. WE ARE WORKING TO ACHIEVE OUR EDUCATION MISSION BY ENGAGING STUDENTS AND TEACHERS IN STEM ACTIVITIES THROUGH SUMMER LEARNING PROGRAMS, FIELD TRIPS, AFTER-SCHOOL PROGRAMING, STEM COMPETITIONS AND SCIENCE FAIRS, INTERNSHIPS, AND PROFESSIONAL DEVELOPMENT WORKSHOPS FOR STEM EDUCATORS. OUR PRIMARY OBJECTIVE IS TO EMBOLDEN STUDENTS WHO POSSESS A PASSION FOR INNOVATION AND DISCOVERY TO PURSUE THEIR INTERESTS AND STRENGTHEN THE STEM COMMUNITY. SOUTHERN RESEARCH IS COMMITTED TO FOSTERING CREATIVITY AND IMPACTING THE FUTURE GENERATION. 1013204 0 1617425 CATALYST BY SOUTHERN RESEARCH IS A UNIQUE PUBLIC HEALTH DATA SYSTEM THAT CONNECTS PATIENT GENOMES (AND OTHER FORMS OF PERSONALIZED MEDICAL DATA, POTENTIALLY INCLUDING TRANSCRIPTOMICS, PROTEOMICS, METABOLOMICS AND OTHERS) TO CLINICAL DATA TO SUPPORT THE HEALTH OF COMMUNITIES. SR WILL ACCOMPLISH THIS GOAL BY INVESTING IN INFRASTRUCTURE TO (A) EXPAND ACCESS TO PERSONALIZED MEDICINE IN ALABAMA, ESPECIALLY IN UNDERSERVED AREAS OF THE STATE; (B) ENSURE ALABAMIANS HAVE MORE EFFECTIVE DIAGNOSTICS DATA TO IDENTIFY AND TREAT UNDERLYING CONDITIONS AND UNDETECTED CO-MORBIDITIES THAT PROVED FATAL FOR MANY ALABAMIANS DURING THE COVID-19 PANDEMIC; AND (C) ENABLE GREATER ACCESS TO CLINICAL TRIALS THROUGHOUT THE STATE. THE CATALYST PROGRAM IS DESIGNED TO ENHANCE AND PROVIDE ADDITIONAL PREVENTATIVE CARE OPTIONS TO ALABAMIANS BY (1) EMPOWERING INDIVIDUALS WITH KNOWLEDGE ABOUT THEIR HEALTH; (2) CONNECTING CLINICAL AND GENOMIC DATA WITH LOCAL HEALTHCARE PROVIDERS; AND (3) ENCOURAGING PARTICIPATION IN PROMISING RESEARCH VIA TARGETED CLINICAL TRIALS. IT IS ALSO DESIGNED TO DEVELOP A DATA INFRASTRUCTURE TO HELP SUPPORT RESEARCH AND CLINICAL INITIATIVES IN BIRMINGHAM AND THROUGHOUT THE STATE OF ALABAMA. 1013204 0 1617425 42471663 1 1 0 1 0 0 0 0 0 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 100 0 1 290 1 0 0 0 0 0 0 0 0 0 0 0 0 X 14 10 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 0 1 1 0 X DAVID A RUTLEDGE 2055812000 2000 NINTH AVENUE SOUTH BIRMINGHAM AL 352555305 CHRISTOPHER S BROWN PHD DIRECTOR 1.00 40.00 X 0 409277 69477 RAY WATTS CHAIRMAN 1.00 40.00 X 0 687821 88048 GENE RUFFNER PAGE JR VICE CHAIRMAN 1.00 0.00 X 0 0 0 FINIS ST JOHN VI DIRECTOR 1.00 40.00 X 0 1119003 128184 JAMEY MCMAHON DIRECTOR 1.00 0.00 X 0 0 0 REGINA BENJAMIN MD DIRECTOR 1.00 0.00 X 0 0 0 LEE STYLINGER III DIRECTOR 1.00 0.00 X 0 0 0 SCOTT PHELPS DIRECTOR 1.00 0.00 X 0 0 0 KEN SIMON DIRECTOR 1.00 0.00 X 0 0 0 MIKE BROCK DIRECTOR 1.00 0.00 X 0 0 0 BOBBIE KNIGHT DIRECTOR 1.00 0.00 X 0 0 0 NEEL VARSHNEY MD DIRECTOR 1.00 0.00 X 0 0 0 ANUPAM AGARWAL MD DIRECTOR 1.00 40.00 X 0 237602 49299 JEFF PEOPLES DIRECTOR 1.00 0.00 X 0 0 0 CE AUGELLI-SZAFRAN VP, SCIENTIFIC PLATFORM 40.00 0.00 X 291569 0 10938 DAVID A RUTLEDGE SENIOR ADVISOR OF FINANCE 40.00 2.00 X 255805 0 21308 JOSHUA D CARPENTER CHIEF EXECUTIVE OFFICER 40.00 0.00 X 403514 0 24138 KEVIN W BURTON VP RESEARCH SERVICES 40.00 0.00 X 282965 0 20324 AVANTI PAUL VP OPERATIONS 40.00 0.00 X 162407 0 11340 ANNA BRANTLEY FRY VP OF PEOPLE & COMMUNITY 40.00 0.00 X 240706 0 24804 ABISHEK KULSHRESHTHA CHIEF OF STAFF 40.00 0.00 X 225322 0 14923 KHALILA BROWN VP MED AFFAIRS & PATIENT ADVCY 40.00 0.00 X 191716 0 19084 OLIVER HAMPTON CHIEF DATA OFFICER 40.00 0.00 X 99345 0 3769 RICARDO BRITO CHIEF OF STAFF 40.00 0.00 X 43374 0 8267 MONICA W MASON INTERIM VP CRO SERVICES 40.00 0.00 X 204884 0 14436 LESTER SMITH JR CFO 40.00 0.00 X 212579 0 20311 JENNIFER PICKENS DIRECTOR INFECTIOUS DISEASE RES 40.00 0.00 X 211951 0 18711 MARIANNE P NURRE SR DIR FINANCIAL COMPLIANCE/ANALYSIS 40.00 0.00 X 200005 0 19129 MICHAEL E HUDSON UNTIL 1023 FORMER PHARMACEUTICAL CONSULTANT 40.00 0.00 X 223940 0 8431 FUSATAKA KOIDE DIR BUSINESS DEVELOPMENT 40.00 0.00 X 393629 0 21742 JOSEPH C RANDALL DIRECTOR TOXICOLOGY & PATH SERV 40.00 0.00 X 193358 0 19984 3837069 2453703 616647 88 0 1 0 BRASFIELD & GORRIE LLC 3021 7TH AVE S BIRMINGHAM AL 35233 CONSTRUCTION AND ENGINEERING 13619587 PRIMGEN PO BOX 118 HINES IL 60141 NHP IMPORTATION 1423368 HOAR CONSTRUCTION TWO METROPLEX DRIVE STE 400 BIRMINGHAM AL 35209 CONSTRUCTION AND ENGINEERING 961330 BALLARD SPAHR LLP 999 PEACHTREE STREET NE SUITE 1600 ATLANTA GA 30309 LEGAL 542253 HM SOUTHEAST CONCRETE LLC 4211 MOUNTAIN TOP RD BIRMINGHAM AL 35242 CONSTRUCTION AND ENGINEERING 387589 15 7100000 158198 7258198 RESEARCH CONTRACTS 541700 37755745 37755745 INTELLECTUAL PROPERTY REVENUE 541900 926094 926094 38681839 6943803 6943803 134300 45738 88562 88562 88562 408381870 411594312 -3212442 -3212442 -3212442 49759960 37755745 0 4746017 X 2614187 1983907 630280 17474291 13261239 4213052 8355599 6341064 2014535 436131 330980 105151 369016 280046 88970 147530 111961 35569 217980 165425 52555 7142678 5420578 1722100 393808 298861 94947 3952658 2999672 952986 1928658 1463659 464999 630865 478763 152102 320846 243490 77356 3423633 2598195 825438 904495 686421 218074 OTHER DIRECT COSTS 2415167 1832870 582297 EQUIPMENT MAINTENANCE 2066083 1567950 498133 DIRECT ANIMAL CARE 1753481 1330717 422764 DUES & SUBSCRIPTIONS 457352 347084 110268 960312 728781 231531 55964770 42471663 13493107 0 3436195 48582006 3294 13443 11099935 5104599 216277 128103 791055 3600881 106978842 58074579 20427281 48904263 166414732 121789264 3813052 0 1808088 1905197 3169736 12082418 211179645 242110174 8046945 14317202 9656534 36577141 9576901 8808716 3464741 3536241 30745121 63239300 X 0 0 12658468 42137766 167776056 136733108 180434524 178870874 211179645 242110174 -6204810 3852408 788752 0 X X 0 1 X 1 1 1 X 1696657 270253 160958 45128927 7258198 54514993 71203397 78155531 76088020 50414850 37755745 313617543 47135 1461 8449 57045 72947189 78427245 76257427 95543777 45013943 368189581 0 0 0 368189581 630116 388345 492581 1450669 7078103 10039814 5404457 3916594 4697213 1400007 0 15418271 6034573 4304939 5189794 2850676 7078103 25458085 1748981 1669020 1882898 1055675 926094 7282668 80730743 84401204 83330119 99450128 53018140 400930334 0.91830 0.93650 0.06350 0.06350 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: INTELLECTUAL PROPERTY REVENUE - 2019 AMOUNT: $ 1,748,981. 2020 AMOUNT: $ 1,669,020. 2021 AMOUNT: $ 1,882,898. 2022 AMOUNT: $ 1,055,675. 2023 AMOUNT: $ 926,094. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 147530 0 1 147530 0 PART II-B, LINE 1: DURING THE YEAR, SRI CONTRACTED WITH A THIRD-PARTY GOVERNMENT RELATIONS AND LOBBYING FIRM THAT CONDUCTED OUR GOVERNMENTAL AFFAIRS WHICH INCLUDED REPRESENTING OUR INTERESTS WITH REGULATORY, LEGISLATIVE, AND EXECUTIVE BODIES AND AGENCIES, OFFERING REGISTERED LOBBYING SERVICES TO PROMOTE SRI'S MISSION AND KEY INITIATIVES WITH THE ABOVE, AND ASSISTING THE ORGANIZATION WITH A BETTER UNDERSTANDING OF THE CHANGES AND DEVELOPMENTS IN THE REGULATORY AND LEGISLATIVE ENVIRONMENTS IN WHICH WE OPERATE. TOTAL PAYMENTS TO THE FIRM MENTIONED ABOVE WERE $89,810 AND OUR INTERNAL COSTS ASSOCIATED WITH THESE ACTIVITIES WERE $57,720, TOTALING $147,530 IN 2023. 11471250 1343469 460343 16280 12338096 13308476 -1241720 573373 22133 11471250 12226041 1670896 557524 30937 13308476 11933466 880109 559151 28383 12226041 10721291 1803175 558088 32912 11933466 0.00000 0.00000 1.00000 0 0 2918352 2918352 30723916 27606155 3117761 694450 694450 0 38656240 29773974 8882266 33985884 33985884 48904263 POST RETIRMENT BENEFITS 1638966 LINE OF CREDIT 819625 ROU LIABILITIES 1077650 3536241 53440126 3852408 45738 3898146 49541980 217980 217980 49759960 55792527 45737 45737 55746790 217980 217980 55964770 PART V, LINE 4: THE INTENDED USE OF THE FUNDS IS TO HELP CERTAIN OUTSTANDING NEWLY-HIRED SCIENTISTS GET THEIR LABORATORIES ESTABLISHED BEFORE THEY HAVE SECURED FUNDING FROM OUTSIDE SPONSORS. PART XI, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSES SHOWN AS OFFSET TO REVENUE ON THE RETURN 45,738. PART XI, LINE 4B - OTHER ADJUSTMENTS: INVESTMENT EXPENSES SHOWN AS OFFSET TO INCOME ON BOOKS 217,980. PART XII, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSES SHOWN AS OFFSET TO REVENUE ON THE RETURN 45,737. PART XII, LINE 4B - OTHER ADJUSTMENTS: INVESTMENT EXPENSES SHOWN AS OFFSET TO INCOME ON BOOKS 217,980. X 1 1 X X 0 1 0 0 0 0 0 0 0 FINIS ST JOHN VI DIRECTOR 0 765736 0 236277 0 99723 0 116223 0 12833 0 1230792 0 0 RAY WATTS CHAIRMAN 0 550325 0 129000 0 71548 0 88048 0 2865 0 841786 0 0 CHRISTOPHER S BROWN PHD DIRECTOR 0 393356 0 12007 0 45615 0 61157 0 10085 0 522220 0 0 JOSHUA D CARPENTER CHIEF EXECUTIVE OFFICER 375990 0 0 0 27524 0 13200 0 10938 0 427652 0 0 0 FUSATAKA KOIDE DIR BUSINESS DEVELOPMENT 139575 0 0 0 254054 0 6931 0 14811 0 415371 0 0 0 KEVIN W BURTON VP RESEARCH SERVICES 251774 0 0 0 31191 0 10600 0 9724 0 303289 0 0 0 CE AUGELLI-SZAFRAN VP, SCIENTIFIC PLATFORM 277386 0 0 0 14183 0 0 0 10938 0 302507 0 0 0 ANUPAM AGARWAL MD DIRECTOR 0 233499 0 0 0 37328 0 49299 0 1247 0 321373 0 0 DAVID A RUTLEDGE SENIOR ADVISOR OF FINANCE 243412 0 0 0 12393 0 10566 0 10742 0 277113 0 0 0 ANNA BRANTLEY FRY VP OF PEOPLE & COMMUNITY 230076 0 0 0 10630 0 9993 0 14811 0 265510 0 0 0 ABISHEK KULSHRESHTHA CHIEF OF STAFF 213758 0 0 0 11564 0 9074 0 5849 0 240245 0 0 0 LESTER SMITH JR CFO 180980 0 0 0 31599 0 8226 0 12086 0 232891 0 0 0 MICHAEL E HUDSON UNTIL 1023 FORMER PHARMACEUTICAL CONSULTANT 168882 0 0 0 55058 0 3546 0 4885 0 232371 0 0 0 JENNIFER PICKENS DIRECTOR INFECTIOUS DISEASE RES 180728 0 0 0 31223 0 7773 0 10938 0 230662 0 0 0 MONICA W MASON INTERIM VP CRO SERVICES 169538 0 0 0 35346 0 7923 0 6513 0 219320 0 0 0 MARIANNE P NURRE SR DIR FINANCIAL COMPLIANCE/ANALYSIS 185597 0 0 0 14408 0 8387 0 10742 0 219134 0 0 0 JOSEPH C RANDALL DIRECTOR TOXICOLOGY & PATH SERV 180653 0 0 0 12705 0 7898 0 12086 0 213342 0 0 0 KHALILA BROWN VP MED AFFAIRS & PATIENT ADVCY 173020 0 0 0 18696 0 7692 0 11391 0 210799 0 0 0 AVANTI PAUL VP OPERATIONS 121513 0 0 0 40894 0 5668 0 5672 0 173747 0 0 0 PART I, LINE 4B RAY WATTS - $71,548 CHRISTOPHER S. BROWN - $45,615 ANUPAM AGARWAL, MD - $37,328 FINIS ST. JOHN VI - $99,723 A THE COOPERATIVE DISTRICT OF THE CITY OF BIRMINGHAM-SOUTHERN RESEARCH INST 273338884 NONEAVAIL 2010-08-31 20000000 SOUTHSIDE AND OXMOOR CAMPUS CAPITAL IMPROVEMENTS 0 1 0 A 11221487 20000000 174000 19826000 2014 0 0 1 1 A 0 1 0 1 1 0 1 0.01200 0 1 A 0 1 0 0 0 0 0 0 1 A 1 SCHEDULE K, PART III, LINES 2, 3(C), 4, 5, 6, 7, 8(A), 8(B), 8(C) THE ORGANIZATION'S OUTSTANDING BONDS WERE ISSUED AS "RECOVERY ZONE FACILITY BONDS" UNDER SECTION 1400U-1(B) OF THE INTERNAL REVENUE CODE. THE OUTSTANDING BONDS ARE CONSIDERED PRIVATE ACTIVITY BONDS AND THEREFORE PRIVATE BUSINESS USE AND PRIVATE PAYMENT AND SECURITY ARE NOT RELEVANT TO SUCH BONDS. SCHEDULE K, PART III, LINE 9, PART IV, LINE 7 AND PART V: THE ORGANIZATION BY ACTION OF ITS FINANCE COMMITTEE OF ITS BOARD OF DIRECTORS ON OCTOBER 30, 2014, ESTABLISHED WRITTEN PROCEDURES. SCHEDULE K, PART IV, LINES 3, 4(A), 4(B), 4(C), 4(D), AND 4(E): AS OF 9/22/2017, THE BOND ISSUE WAS CONVERTED FROM A VARIABLE RATE TO A FIXED RATE. DURING THE VARIABLE RATE PERIOD, THE ORGANIZATION ENTERED INTO A QUALIFIED HEDGE WITH RESPECT TO THE BOND ISSUE WITH BBVA COMPASS, WITH A TERM OF 6.0 YEARS. SUCH HEDGE TERMINATED BY ITS TERMS ON 9/1/2017. FORM 990, PART III, LINE 2 THE ORGANIZATION STARTED INVESTING INFRASTRUCTURE IN THE CATALYST DIVISION IN 2023 TO CONNECT PATIENT GENOMES TO CLINICAL DATA TO SUPPORT THE HEALTH OF COMMUNITIES. FORM 990, PART VI, SECTION A, LINE 7A THE DIRECTORS SHALL BE APPOINTED BY THE PRESIDENT OF THE UNIVERSITY OF ALABAMA AT BIRMINGHAM, A RELATED GOVERNMENTAL ENTITY, PROVIDED SUCH APPOINTMENT IS APPROVED BY THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA. FORM 990, PART VI, SECTION A, LINE 7B THE GOVERNING DOCUMENTS STATE THAT THE ORGANIZATION MAY NOT ADOPT A PLAN OF MERGER, CONSOLIDATION OR DISSOLULTION AND CANNOT SELL, LEASE, EXCHANGE, MORTGAGE, PLEDGE OR OTHERWISE DISPOSE OF ALL OR SUBSTANTIALLY ALL OF THE ORGANIZATION'S ASSETS WITHOUT APPROVAL FROM THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA. FURTHERMORE, THE GOVERNING DOCUMENTS MAY NOT BE AMENDED WITHOUT PRIOR CONSENT FROM THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA. FORM 990, PART VI, SECTION B, LINE 11B THE BOARD OF DIRECTORS HAS ADOPTED THE POLICY THAT THE FINANCE COMMITTEE WOULD REVIEW AND APPROVE THE FORM 990 PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C OFFICERS, DIRECTORS, AND KEY/HIGHLY COMPENSATED EMPLOYEES ARE REQUIRED TO DISCLOSE ANNUALLY ANY POTENTIAL CONFLICTS OF INTEREST OR CERTIFY THAT NO SUCH CONFLICTS EXIST. THE ORGANIZATION INVESTIGATES DISCLOSURES OF ANY POTENTIAL CONFLICTS AND TAKES STEPS TO MITIGATE THE OCCURRENCE OF ACTUAL CONFLICTS OF INTEREST. SHOULD A CONFLICT OF INTEREST OCCUR, THE OFFICER, DIRECTOR, AND KEY/HIGHLY COMPENSATED EMPLOYEE WILL BE EXCUSED FROM VOTING ON MATTERS ASSOCIATED WITH THE ENTITY THAT THE CONFLICT OF INTEREST AROSE WITH. CERTAIN BUSINESS RELATIONSHIPS EXISTING BETWEEN AN ENTITY IN CONNECTION WITH WHICH A DIRECTOR, OFFICER AND/OR KEY EMPLOYEE OF SR MAY BE ASSOCIATED AND SR MAY BE THE SUBJECT OF A MANAGEMENT PLAN DESIGNED TO MONITOR THE BUSINESS ACTIVITIES BETWEEN SUCH ENTITY AND SR AND ENSURE THAT THE INVOLVEMENT OF THE INTERESTED DIRECTOR, OFFICER AND/OR KEY EMPLOYEE IS LIMITED OR RESTRICTED TO ENSURE NO UNDUE INFLUENCE ON SUCH ACTIVITIES MAY BE EXERTED. FORM 990, PART VI, SECTION B, LINE 15 IN EARLY 2023, THE WILSON GROUP WAS ENGAGED TO CONDUCT A COMPETITIVE ASSESSMENT OF THE TOTAL CASH COMPENSATION FOR THE EXECUTIVE LEADERSHIP TEAM (ELT) OF SOUTHERN RESEARCH (SR). OF NOTE, THE WILSON GROUP HAS CONDUCTED SIMILAR STUDIES IN 2018 AND 2021, THE METHODOLOGY USED IN THIS ANALYSIS IS LIKE PREVIOUS COMPENSATION STUDIES CONDUCTED BY THIS TEAM. THIS UPDATED ANALYSIS HAS BEEN FACILITATED BY AN EXTERNAL HR CONSULTANT, ALESIA JONES, UNDER THE DIRECTION OF THE SR'S BOARD'S FINANCE COMMITTEE. THE RESULTS OF THE COMPENSATION STUDY WERE PRESENTED TO THE CHAIR OF THE BOARD AND THE CHAIR OF THE FINANCE COMMITTEE IN EARLY JULY 2023. FORM 990, PART VI, SECTION C, LINE 19 AS A GENERAL RULE, THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, OR FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. ANY WRITTEN REQUEST BY THE PUBLIC WOULD BE REVIEWED AND ACTED UPON BY THE BOARD. FORM 990, PART IX, LINE 11G OUTSIDE SERVICES: PROGRAM SERVICE EXPENSES 3,081,850. MANAGEMENT AND GENERAL EXPENSES 979,094. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 4,060,944. CONSULTANTS: PROGRAM SERVICE EXPENSES 2,310,450. MANAGEMENT AND GENERAL EXPENSES 734,022. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 3,044,472. OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 28,278. MANAGEMENT AND GENERAL EXPENSES 8,984. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 37,262. FORM 990, PART XII, LINE 2C: THE FINANCE COMMITTEE OF THE ORGANIZATION ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 THIRD AVENUE SOUTH BIRMINGHAM AL 352941150 636005396 HIGHER EDUCATON FACILITY AL POLITICAL SUBDVISION N/A 0 SOUTHERN RESEARCH INSTITUTE VEBA 2000 NINTH AVENUE SOUTH BIRMINGHAM AL 35205 562439567 VOLUNTARY EMPLOYEE BENEFIT ASSOCIATION AL 501(C)(9) SOUTHERN RESEARCH INSTITUTE 0 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA 500 UNIVERSITY BLVD EAST TUSCALOOSA AL 35401 636001138 HIGHER EDUCATON FACILITY AL 501(C)(3) N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0